Appili Therapeutics Past Earnings Performance
Past criteria checks 0/6
Appili Therapeutics's earnings have been declining at an average annual rate of -13.5%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 47.4% per year.
Key information
-13.5%
Earnings growth rate
6.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 47.4% |
| Return on equity | n/a |
| Net Margin | -464.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Appili Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -5 | 4 | 5 |
| 30 Sep 23 | 1 | -8 | 4 | 5 |
| 30 Jun 23 | 0 | -8 | 5 | 4 |
| 31 Mar 23 | 0 | -9 | 5 | 4 |
| 31 Dec 22 | 0 | -10 | 5 | 3 |
| 30 Sep 22 | 1 | -11 | 5 | 6 |
| 30 Jun 22 | 1 | -20 | 5 | 16 |
| 31 Mar 22 | 1 | -25 | 5 | 21 |
| 31 Dec 21 | 1 | -27 | 6 | 24 |
| 30 Sep 21 | 0 | -28 | 6 | 24 |
| 30 Jun 21 | 0 | -19 | 6 | 15 |
| 31 Mar 21 | 0 | -14 | 5 | 10 |
| 31 Dec 20 | 0 | -11 | 5 | 6 |
| 30 Sep 20 | 0 | -8 | 5 | 4 |
| 30 Jun 20 | 0 | -6 | 4 | 3 |
| 31 Mar 20 | 0 | -5 | 4 | 2 |
| 31 Dec 19 | 0 | -5 | 4 | 2 |
| 30 Sep 19 | 0 | -5 | 4 | 3 |
| 30 Jun 19 | 0 | -6 | 4 | 3 |
| 31 Mar 19 | 0 | -4 | 3 | 3 |
| 31 Dec 18 | 0 | -4 | 3 | 4 |
| 31 Mar 18 | 0 | -4 | 2 | 4 |
Quality Earnings: APLI.F is currently unprofitable.
Growing Profit Margin: APLI.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APLI.F is unprofitable, and losses have increased over the past 5 years at a rate of 13.5% per year.
Accelerating Growth: Unable to compare APLI.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APLI.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: APLI.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.